Skip to content

Ana M. Peiró

3 papers in the library · publishing 2003-2005

Papers

Sort Most recent Most cited

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Clinical Pharmacokinetics 2005 Mireia Segura, Magí Farré, Simona Pichini et al.

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative typically used for recreational purposes. The participation of cytochrome P450 (CYP) 2D6 in the oxidative metabolism of MDMA may suggest an increased risk of acute toxicity in CYP2D6 poor metabolisers. This study was aimed at assessing the contribution of CYP2D6 to MDMA disposition in vivo using paroxetine as a...

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Psychopharmacology May 2004 M Farré, Rafael de la Torre, Brian O Mathúna et al.

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is increasingly used by young people for its euphoric and empathic effects. MDMA presents non-linear pharmacokinetics, probably by inhibition of cytochrome P450 isoform 2D6. Users are known to often take more than one dose per session. This practice could have serious implications for the toxicity of MDMA. To evaluate the pharmacological...

Estudios controlados en humanos de éxtasis

Adicciones December 15, 2003 Magí Farré Albadalejo, Pere N. Roset Arissó, Rafael de la Torre et al.

Objetivo: recopilar y analizar la información sobre los efectos de la MDMA obtenida en estudios controlados en humanos. Método: la mayoría de ensayos analizados han sido de diseño enmascarado a doble ciego, cruzados, con asignación aleatoria a la secuencia de tratamientos, y controlados con placebo y/o fármaco patrón. Resultados: además del incremento de la presión y frecuencia cardíaca, la...